(Q44251411)

1 December 2017

Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. (English)

1 reference

1 December 2017

1 reference

1 reference

A F Stättermayer

1

1 reference

1 December 2017

R Strassl

2

1 reference

1 December 2017

A Maieron

3

1 reference

1 December 2017

K Rutter

4

1 reference

1 December 2017

R Stauber

5

1 reference

1 December 2017

M Strasser

6

1 reference

1 December 2017

S Beinhardt

7

1 reference

1 December 2017

C Datz

8

1 reference

1 December 2017

T-M Scherzer

9

1 reference

1 December 2017

P Steindl-Munda

10

1 reference

1 December 2017

M Gschwantler

11

1 reference

1 December 2017

M Trauner

12

1 reference

1 December 2017

H Hofer

13

1 reference

1 December 2017

P Ferenci

14

1 reference

1 December 2017

language of work or name

English

0 references

publication date

10 November 2013

1 reference

Alimentary Pharmacology & Therapeutics

1 December 2017

1 reference

1 December 2017

39

1 reference

1 December 2017

1

1 reference

1 December 2017

104-111

1 reference

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 December 2017

1 reference

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.

21 January 2018

1 reference

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

21 January 2018

1 reference

Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.

21 January 2018

1 reference

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

21 January 2018

1 reference

Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection

21 January 2018

1 reference

Association of the IFNL4-ΔG Allele With Impaired Spontaneous Clearance of Hepatitis C Virus

21 January 2018

1 reference

IL-28, IL-29 and their class II cytokine receptor IL-28R

21 January 2018

1 reference

Viral Infections Activate Types I and III Interferon Genes through a Common Mechanism

21 January 2018

1 reference

IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex

21 January 2018

1 reference

Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.

21 January 2018

1 reference

IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.

21 January 2018

1 reference

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus

21 January 2018

1 reference

Introduction to the genetics and biology of interleukin-28B.

21 January 2018

1 reference

Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response

21 January 2018

1 reference

Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response

21 January 2018

1 reference

A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.

21 January 2018

1 reference

Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection

21 January 2018

1 reference

High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials

21 January 2018

1 reference

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

21 January 2018

1 reference

IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction

21 January 2018

1 reference

Regulation of hepatic innate immunity by hepatitis C virus

21 January 2018

1 reference

IL28B rs12979860 genotype and spontaneous clearance of hepatitis C virus in a multi-ethnic cohort of injection drug users: evidence for a supra-additive association

21 January 2018

1 reference

Faldaprevir and deleobuvir for HCV genotype 1 infection.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/APT.12547

1 reference

1 December 2017

1 reference